Syndax stock falls 16% as Phase II fibrosis study misses primary goal

Syndax stock falls 16% as Phase II fibrosis study misses primary goal: the analysis positions SNDX, VKTX and MDGL under pressure; confidence high.

Analyzed 2026-10-14 — point-in-time, never revised. Outcomes are scored against SPY and published either way.

Who's next

▼ SNDX Syndax — impact -88 · confidence high · horizon immediate · 1st order
Axatilimab’s failed fibrosis study eliminates Syndax’s IPF revenue opportunity and sharply reduces the program’s future cash flows.
Chain: MAXPIRE Phase 2 misses primary endpoint in IPF → axatilimab fibrosis expansion program discontinued by sponsor → peak sales model loses IPF revenue line → risk-adjusted valuation and share price reset lower
What would break the call: A subgroup or biomarker analysis supports a revised Phase 3 IPF design with partner funding.
▼ VKTX Viking — impact -40 · confidence low · horizon quarters · 3rd order
Viking NASH fibrosis program faces delayed approval timelines after the related Syndax trial miss.
Chain: fibrosis endpoint failure chills sector sentiment → investors discount fibrosis-regression claims across indications → Viking metabolic liver program multiple compresses → cost of equity rises before pivotal spend
What would break the call: Viking posts positive fibrosis improvement data that separates metabolic liver disease from lung fibrosis.
▼ MDGL Madrigal — impact -30 · confidence low · horizon quarters · 3rd order
Madrigal liver fibrosis drug candidate faces higher regulatory scrutiny after the Syndax result.
Chain: fibrosis endpoint miss renews regulator caution → agency scrutiny of fibrosis surrogate endpoints tightens → Madrigal label expansion timeline risk rises → forward revenue estimates get discounted
What would break the call: Madrigal reports positive outcomes data in compensated cirrhosis that validates its fibrosis endpoint.
▼ TVRD Tvardi Therapeutics — impact -30 · confidence low · horizon immediate · 3rd order
Tvardi faces tougher investor scrutiny on fibrosis endpoints, which raises its cost of capital before pivotal spending.
Chain: peer fibrosis trial misses primary endpoint → investors reprice IPF development risk higher → Tvardi financing window narrows before pivotal study → cost of capital rises and dilution increases
What would break the call: Tvardi secures a partnership or non-dilutive funding that removes the financing overhang.
▼ ATYR aTyr Pharma — impact -20 · confidence low · horizon immediate · 3rd order
aTyr pursues interstitial lung disease endpoints that investors discount further after another mid-stage fibrosis readout misses.
Chain: another interstitial lung disease readout fails → investors derate lung immunology endpoint probability → aTyr efzofitimod probability of success discounted → valuation and financing terms worsen
What would break the call: aTyr delivers positive sarcoidosis data that investors treat as mechanistically distinct.
▼ INCY Incyte — impact -14 · confidence medium · horizon immediate · 1st order
The failed fibrosis study ends axatilimab’s IPF development, eliminating Incyte’s collaboration economics.
Chain: axatilimab is an Incyte and Syndax collaboration → IPF indication discontinued after endpoint miss → shared expansion milestones and royalties disappear → long-term Niktimvo revenue forecast narrows
What would break the call: Incyte guides to other axatilimab indications that replace the lost IPF opportunity.
▼ IQV IQVIA — impact -8 · confidence low · horizon quarters · 2nd order
Cancelled fibrosis trials reduce clinical research awards and lengthen sales cycles for IQVIA research and development solutions.
Chain: sponsor discontinues fibrosis development program → planned clinical spending removed from CRO pipeline → IQVIA net new bookings soften → backlog growth and revenue conversion slow
What would break the call: IQVIA reports accelerating research and development solutions bookings in its next quarter.
▼ MEDP Medpace — impact -8 · confidence low · horizon quarters · 2nd order
Medpace books fewer enrollment milestones when a sponsor halts a fibrosis program and redirects budget elsewhere.
Chain: sponsor halts fibrosis development program → planned Phase 3 trial spending cancelled → CRO enrollment and service milestones not booked → backlog and revenue conversion slow
What would break the call: Medpace reports rising net new bookings that show no biotech demand deterioration.
▼ CRL Charles River Laboratories — impact -6 · confidence low · horizon quarters · 3rd order
Charles River sells preclinical models and safety studies that shrink when sponsors cancel discovery work in fibrosis.
Chain: fibrosis clinical failure discourages discovery investment → sponsors cut preclinical fibrosis model and safety work → Charles River research services orders decline → discovery segment revenue growth slows
What would break the call: Charles River raises guidance on improving biotech demand and discovery bookings.
▼ ICLR Icon — impact -6 · confidence low · horizon quarters · 2nd order
Icon loses backlog as biotech clients trim mid-stage respiratory trials following another high-profile endpoint failure.
Chain: high-profile respiratory endpoint failure chills sponsor budgets → biotech clients delay mid-stage respiratory trials → Icon net new business awards soften → backlog burn and revenue growth slow
What would break the call: Icon reports improving book-to-bill driven by large pharma demand offsetting biotech weakness.
▼ TMO Thermo Fisher Scientific — impact -6 · confidence low · horizon quarters · 3rd order
Fewer fibrosis trials cut demand for clinical supplies reagents and bioprocessing services sold into biotech sponsors.
Chain: fibrosis trial failure trims biotech development budgets → sponsors reduce reagent and clinical supply orders → Thermo Fisher pharma services demand softens → life sciences solutions revenue growth slows
What would break the call: Thermo Fisher guides to recovering biotech instrument and services demand.

Already moved

▲ PLRX Pliant — impact +45 · confidence medium · horizon immediate · 2nd order
Syndax’s failed study reduces competitive supply, increasing bexotegrast’s scarcity value in partnering discussions.
Chain: rival IPF mechanism fails mid-stage readout → fewer late-stage competitors chasing same patient pool → bexotegrast scarcity value rises with potential partners → partnering terms and valuation improve
What would break the call: Pliant reports its own tolerability or efficacy setback in the bexotegrast program.
▲ RNTX Rein Therapeutics — impact +40 · confidence low · horizon weeks · 2nd order
Rein advances LTI-03 into a thinner competitive field, which lifts the strategic value of its inhaled fibrosis program.
Chain: competing IPF mechanism exits development → inhaled fibrosis field becomes less crowded → LTI-03 strategic and partnering value rises → small-cap valuation re-rates on scarcity
What would break the call: Rein data disappoint or a cash raise at a deep discount offsets scarcity value.
▲ GALT Galectin — impact +35 · confidence low · horizon quarters · 3rd order
Syndax trial failure removes a competitor and raises Galectin fibrosis drug pricing power.
Chain: lung fibrosis readout fails on primary endpoint → investors question fibrosis-regression mechanisms broadly → Galectin cited as remaining fibrosis option → speculative valuation moves on scarcity narrative
What would break the call: Galectin fails its own cirrhosis endpoint or dilutes heavily to fund a pivotal trial.
▲ KURA Kura Oncology — impact +20 · confidence low · horizon weeks · 3rd order
Kura competes against a rival whose spending power weakens, which eases commercial pressure on its menin inhibitor launch.
Chain: Syndax fibrosis program ends and spending shifts → Syndax resources concentrate on Niktimvo and revumenib → menin inhibitor competition stays intense → Kura commercial pressure barely eases
What would break the call: Syndax redirects freed fibrosis budget into a larger revumenib commercial push.
▲ UTHR United Therapeutics — impact +18 · confidence high · horizon immediate · 2nd order
Syndax’s failed study removes a competing fibrosis therapy, extending Tyvaso’s franchise and supporting prescription volumes in related indications.
Chain: IPF disease-modifying candidate exits development → fibrotic lung patients lack progression-halting options → Tyvaso remains core therapy in PH-ILD → prescription volumes and franchise duration hold
What would break the call: Generic or alternative inhaled treprostinil entry erodes Tyvaso volumes regardless of fibrosis pipeline news.
▲ LQDA Liquidia — impact +18 · confidence low · horizon quarters · 2nd order
Failure of a disease-modifying fibrosis therapy keeps inhaled treprostinil the main option for pulmonary hypertension with interstitial lung disease.
Chain: IPF disease-modifying candidate discontinued after endpoint miss → fibrotic lung patients keep progressing toward pulmonary hypertension → inhaled treprostinil addressable population stays intact → Yutrepia prescription volume forecasts hold
What would break the call: Litigation or payer coverage setbacks block Yutrepia uptake regardless of fibrosis pipeline news.
▲ TRVI Trevi Therapeutics — impact +16 · confidence low · horizon quarters · 2nd order
Trevi sells symptom control for fibrosis cough, and that demand holds when disease-modifying alternatives fail to arrive.
Chain: disease-modifying IPF option fails to advance → chronic cough symptom burden persists in patients → haduvio addressable population remains intact → future launch volume assumptions hold
What would break the call: Trevi misses its own chronic cough endpoint in the pivotal IPF program.
▲ BMY Bristol Myers Squibb — impact +14 · confidence low · horizon quarters · 2nd order
Bristol Myers gains room for admilparant in lung fibrosis as rival macrophage-targeting approaches lose scientific credibility.
Chain: macrophage-targeted IPF approach fails mid-stage → LPA1 mechanism gains relative credibility → admilparant faces one fewer late entrant → future IPF franchise share assumptions improve
What would break the call: Admilparant Phase 3 data disappoint and remove the IPF opportunity for Bristol Myers.
▲ INSM Insmed — impact +12 · confidence low · horizon quarters · 2nd order
Insmed markets inhaled treprostinil toward fibrotic lung patients who still lack therapies that halt disease progression.
Chain: IPF disease-modifying candidate discontinued → patients remain dependent on symptomatic and vasodilator therapy → treprostinil palmitil opportunity in fibrotic lung disease holds → forecast volumes and launch economics supported
What would break the call: Insmed inhaled treprostinil data miss in pulmonary hypertension with interstitial lung disease.

Sources

Related scenarios

Stocks in this scenario

SNDX · VKTX · MDGL · TVRD · ATYR · INCY · IQV · MEDP · CRL · ICLR · TMO · PLRX · RNTX · GALT · KURA · UTHR · LQDA · TRVI · BMY · INSM

News events · All scenarios · Pricing · Track record · Methodology · Map your own scenario